Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print For Stanford scientists, RNAi gene therapy takes two steps forward, one step back

For Stanford scientists, RNAi gene therapy takes two steps forward, one step back

May 25, 2006

STANFORD, Calif.-Three years ago Mark Kay, MD, PhD, published the first results showing that a hot new biological phenomenon called RNA interference was an effective gene-therapy technique in mice. That finding kicked off an RNAi gene therapy research flurry amongst both academic and industry research groups.

Now, with three human RNAi gene therapy trials under way, Kay's initial excitement is proving to be on target. However, reaching this point hasn't been without challenges. In the latest twist, Kay, professor of genetics and of pediatrics at the Stanford University School of Medicine, and postdoctoral fellow Dirk Grimm, PhD, report an unexpected side effect of another type of RNAi gene therapy not on trial-mice in that study suffered liver toxicity from the treatment and some died. Despite that initial result, to be published in the May 25 issue of Nature, Kay and Grimm went on to find a way that shows promise in resolving this side effect.




"Just like any other new drug, it is just going to mean that we need to proceed cautiously," Kay said.

In traditional gene therapy the inserted DNA produces a gene to replace one that carries a mutation. In hemophilia, for example, the inserted gene makes a protein that is missing in the blood of people with the disease. RNAi gene therapy has the opposite effect. The inserted DNA produces a molecule called an shRNA, which turns off an overactive gene.

With key genes shut off, viruses such as hepatitis B, hepatitis C or HIV are unable to multiply and cause disease. However, some reports had suggested that RNAi gene therapy might induce an immune reaction or switch off the wrong gene or genes.

As these concerns faded, things began looking up for RNAi with three RNAi therapies now in human trials-two for macular degeneration and one for a type of pneumonia. However, these studies involve simply infusing the RNAi molecules into the eye or lung. The RNAi effects in these therapies aren't permanent. Instead, patients may need to receive repeat doses of the RNAi.

If RNAi is going to be viable as a therapy for organ-wide diseases such as hepatitis B or C, it will have to stick around. Kay and Grimm felt they needed to show that the shRNA molecule made by the therapeutic gene would continue to be safe if it existed in high levels in a tissue over long periods of time.

Instead of proving the safety of RNAi gene therapy, the pair found that persistent, high levels of the shRNA made the mice sick, and in some cases the mice even died.

The problem, it seems, is that in the process of shutting down the viral genes, therapeutic shRNA molecules also hijack the cell's normal RNAi machinery. With that machinery otherwise engaged, it's not available to carry out its normal role in the cell.

"One benefit of RNAi gene therapy is that it uses the body's own machinery, making it an effective approach," Kay said. "However, the detriment of RNAi gene therapy turns out to be that it uses the body's own machinery."

Nonetheless, Grimm and Kay bypassed the toxic effects by producing the therapeutic shRNA molecule at lower levels. They were able to prevent the human hepatitis B virus from replicating in mouse liver for more than half a year after a single therapy using this technique. Kay and Grimm said they have more work to do to learn the best way of making shRNA at levels high enough to be effective as gene therapy but low enough to avoid toxicity in humans.

Kay said that cancer and viral diseases such as AIDS or hepatitis B and C are likely targets for future RNAi therapies. In order to get to these trials, Kay said he and Grimm would need to work out what caused the toxic effects in mice and further develop strategies for circumventing that reaction. He expects that trials already under way will help him and others figure out the best way to bring RNAi gene therapy safely to humans.

Stanford University Medical Center



Related RNAi Current Events and RNAi News Articles RNAi Current Events and RNAi News RSS RNAi Current Events and RNAi News RSS
RNA interference found in budding yeasts
Some budding yeast species have the ability to silence genes using RNA interference (RNAi). Until now, most researchers thought that no budding yeasts possess the RNAi pathway because Saccharomyces cerevisiae, the protoypical model budding yeast does not.

Safe seed: Researchers yielding good results on food cotton in field
Field trials of a new cotton are verifying previous lab and greenhouse studies indicating the crop could become a source of protein for millions of malnourished people in the world.

Study reveals how a common virus eludes the immune system
Viruses have numerous tricks for dodging the immune system. In the September 7, 2009 issue of the Journal of Cell Biology, Stagg et al. reveal a key detail in one of these stratagems, identifying a protein that enables cyto¬megalovirus to shut down an antiviral defense (online August 31).

An effective target of biological therapy for hepatocellular carcinoma
It has been shown that constitutively activated STAT3 is detected in many HCC cell lines and tissues. This suggests that STAT3 is a promising molecular target for HCC gene therapy.

The downside of microtubule stability
Stalled microtubules might be responsible for some cases of the neurological disorder Charcot-Marie-Tooth (CMT) disease.

Hitting cancer where it hurts
Two studies in the May 29th issue of Cell, a Cell Press publication, have taken advantage of new technological advances to search for and find previously unknown weaknesses in a hard to treat form of cancer.

Cancer cells need normal, nonmutated genes to survive
Corrupt lifestyles and vices go hand in hand; each feeds the other. But even the worst miscreant needs customary societal amenities to get by.

The future of personalized cancer treatment: An entirely new direction for RNAi delivery
In technology that promises to one day allow drug delivery to be tailored to an individual patient and a particular cancer tumor, researchers at the University of California, San Diego School of Medicine, have developed an efficient system for delivering siRNA into primary cells.

p90RSK: A new therapeutic target for liver fibrosis?
Cirrhosis is a world wide, bad prognosis liver disease and characterized by excessive collagen deposition and liver function damage.

CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die
When cells undergo potentially catastrophic damage, for example as a result of exposure to ionizing radiation, they must make a decision: either to fix the damage or program themselves for death, a process called apoptosis.
More RNAi Current Events and RNAi News Articles
Rnai: A Guide to Gene Silencing (Manual)

Rnai: A Guide to Gene Silencing (Manual)
by Gregory J. Hannon (Author), Gregory J. Hannon (Editor)

The ability of double stranded RNA to inhibit the expression of genes with an appropriate sequence can be harnessed to silence target genes in vitro in a new and powerful way. This volume combines reliable RNAi protocols for a variety of species with discussion of strategies for the effective design of experiments using this important new technique that is changing the way experimental science is done.

RNA Interference (Current Topics in Microbiology and Immunology)

RNA Interference (Current Topics in Microbiology and Immunology)
by Patrick J. Paddison (Author), Patrick J. Paddison (Editor), Peter K. Vogt (Editor)

In the last few years the major effect that RNAi has had in invertebrate systems like C.elegans and drosophila is beginning to take hold in mammalian systems through both single gene knockdown experiments and genome-scale screens. In the next decade, there will no doubt be both notable successes and failures as we attempt to apply this genetic tool to various biological problems for the first time in academia and industry. Through the introduction of RNAi, mammalian systems have finally gained admittance to the pantheon of model genetic systems.



Battle Ship JC

Battle Ship JC
by Atari

Hundreds of naval, air, and undersea battle sequences

RNAi: Design and Application (Methods in Molecular Biology)

RNAi: Design and Application (Methods in Molecular Biology)
by Sailen Barik (Editor)

RNA interference (RNAi), in which RNA silences RNA, is the most recent discovery to revolutionize the study of biology. In RNAi: Design and Applications, leaders in the field contribute state-of-the-art, easy to follow methods and bench protocols designed for practical, everyday use of RNAi in biological research. Divided into two parts, this comprehensive volume covers fundamentals including designs of RNAi, biochemical assay protocols for the major components of RNAi, and study of potential off-target effects, followed by an extensive section covering various applications of RNAi in diverse model organisms and systems, from antiviral and anticancer applications to altering flower color in plants.

Cutting edge and clearly written, RNAi: Design and Applications enables a...

  Club Extinction [VHS]
Starring: Alan Bates, Jennifer Beals, Jan Niklas, Hanns Zischler, Benoît Régent
Directed By: Claude Chabrol
Also With: Jean Rabier (Cinematographer), Claude Chabrol (Writer), Ingrid Windisch (Producer), Konstantin Thoeren (Producer), Norbert Jacques (Writer), Sollace Mitchell (Writer), Thomas Bauermeister (Writer)



RNAi (Advanced Methods)

RNAi (Advanced Methods)
by Mart Latterich (Author)

One of the major recent discoveries in molecular and cellular biology is that small double-stranded RNA molecules selectively turn off gene expression in all types of cell, a phenomenon known as RNA silencing. This discovery led to the development of RNA interference (known as RNAi) as a powerful research tool in the functional study of individual genes and their products, and in functional genomics. In RNAi, specific small double-stranded RNA molecules (small interfering RNAs or siRNAs) are introduced into cells to selectively silence certain genes.


RNAi covers the basic concepts and mechanisms of RNAi, transfection of cells with siRNAs, the design and validation of RNAi reagents, RNAi techniques in different organisms, large-scale RNAi screening, applications of RNAi in...

Therapeutic Applications of RNAi: Methods and Protocols (Methods in Molecular Biology)

Therapeutic Applications of RNAi: Methods and Protocols (Methods in Molecular Biology)
by John F. Reidhaar-Olson (Editor), Cristina M. Rondinone (Editor)

The phenomenon of RNA interference has rapidly moved from groundbreaking scientific discovery to promising therapeutic approach. However, even as RNAi-based drugs enter the clinic, significant challenges remain, particulary in the area of delivery. Therapeutic Applications of RNAi provides detailed protocols in key areas of current focus, including testing of delivery vehicles, identification of appropriate model systems, and evaluation of the effects of RNAi in vivo. Produced by a team of internationally renowned authors, the volume describes the therapeutic applications of RNAi and potential pitfalls in oncology, viral infections and CNS disease, using a variety of delivery methods, including liposomes, peptide-based nanoparticles, polycationic polymers, and viral vehicles. Written...

RNA Interference (RNAi): The Nuts & Bolts of siRNA Technology (Nuts & Bolts Series)

RNA Interference (RNAi): The Nuts & Bolts of siRNA Technology (Nuts & Bolts Series)
by David Engelke (Author)

This book offers protocols and advise for the use of RNA Interference for knowking down expression of target genes in a number of different eukaryotes. Varied applications in mammalian systems are explored in depth by authors currently working at the leading edge of RNA interference methodologies.

Chapters of the book discuss RNAi in plants, Drosophila, C. elegans, and mammalian systems. As other "Nuts&Bolts series" books, RNA Intereference offeres detailed protocols and experimental tips.

  RNAi licenses database platform from GeneGo.(RCL)(GeneGo, Inc): An article from: BIOTECH Patent News
by Biotech Patent News (Publisher)

This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on January 1, 2005. The length of the article is 492 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: RNAi licenses database platform from GeneGo.(RCL)(GeneGo, Inc)
Publication: BIOTECH Patent News (Newsletter)
Date: January 1, 2005
Publisher: Biotech Patent News
Volume: 19 Issue: 1

Distributed by Thomson Gale

  CytRx provides update on RNAi-based drug discovery programs - progress made toward developing medicines to treat obesity and type 2 diabetes.: An article from: BIOTECH Patent News
by Thomson Gale (Publisher)

This digital document is an article from BIOTECH Patent News, published by Thomson Gale on February 1, 2006. The length of the article is 923 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: CytRx provides update on RNAi-based drug discovery programs - progress made toward developing medicines to treat obesity and type 2 diabetes.
Publication: BIOTECH Patent News (Newsletter)
Date: February 1, 2006
Publisher: Thomson Gale
Volume: 20 Issue: 2

Distributed by Thomson...

© 2009 BrightSurf.com